PASG

+ Watchlist + Portfolio

Passage Bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.51
52-Week Range: $3.29 – $20.00
Market Cap: $14.42M
P/E (TTM): —
EPS (TTM): -11.32
Dividend Yield: —

Advanced Metrics

Price/Book: 3.23
PEG Ratio: —
Return on Equity: -169.09%
Return on Assets: -45.62%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.22
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-14.81M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-9.64M

PASG Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$86.05M	$61.42M	$40.18M	$23.28M
Selling, General & Admin	$49.34M	$41.58M	$24.99M	$19.88M
Operating Expenses	$135.39M	$103.00M	$65.17M	$43.15M
Operating Income	-$135.39M	-$103.00M	-$65.17M	-$43.15M
EBITDA	-$131.72M	-$99.28M	-$62.09M	-$42.42M
Pretax Income	-$136.13M	-$102.06M	-$64.77M	-$45.52M
Net Income	-$136.13M	-$102.06M	-$64.77M	-$45.52M
Diluted EPS	-50.00	-37.20	-21.40	-14.35
Diluted Shares	2.72M	2.74M	3.02M	3.17M

PASG Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.60M	$21.71M	$37.57M	$46.30M
Current Assets	$197.04M	$117.96M	$78.81M	$47.76M
Total Assets	$243.55M	$150.54M	$102.41M	$62.28M
Current Liabilities	$18.35M	$16.34M	$19.36M	$23.08M
Total Debt	$27.11M	$26.29M	$25.48M	$24.01M
Total Liabilities	$42.18M	$39.26M	$41.15M	$43.53M
Retained Earnings	-$492.41M	-$594.47M	-$659.24M	-$704.76M
Shareholders' Equity	$201.37M	$111.28M	$61.26M	$18.75M
Working Capital	$178.69M	$101.62M	$59.45M	$24.68M

PASG Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$118.21M	-$78.26M	-$47.96M	-$31.51M
Capital Expenditure	-$5.27M	-$146.00K	-$34.00K	—
Free Cash Flow	-$123.48M	-$78.41M	-$47.99M	-$31.51M
Depreciation & Amortisation	$3.68M	$3.72M	$3.08M	$728.00K
Stock-Based Compensation	$18.95M	$10.92M	$5.82M	$3.00M
Investing Cash Flow	$25.20M	$65.24M	$54.95M	$40.22M
Financing Cash Flow	-$1.35M	$135.00K	$8.87M	$23.00K
Net Change in Cash	-$94.36M	-$12.89M	$15.86M	$8.73M

PASG Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.74M	$5.81M	$4.31M	$5.42M	$4.09M
Selling, General & Admin	$6.08M	$4.52M	$4.35M	$4.92M	$4.79M
Operating Expenses	$13.82M	$10.33M	$8.65M	$10.34M	$8.88M
Operating Income	-$13.82M	-$10.33M	-$8.65M	-$10.34M	-$8.88M
EBITDA	-$13.62M	-$10.16M	-$8.47M	-$10.16M	-$8.75M
Pretax Income	-$15.40M	-$9.38M	-$7.75M	-$12.98M	-$7.56M
Net Income	-$15.40M	-$9.38M	-$7.75M	-$12.98M	-$7.56M
Diluted EPS	-4.87	-2.96	-2.44	—	-2.36
Diluted Shares	3.16M	3.17M	3.18M	—	3.21M

PASG Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$63.36M	$57.63M	$52.77M	$46.30M	$33.34M
Current Assets	$66.67M	$60.31M	$55.73M	$47.76M	$34.74M
Total Assets	$86.01M	$79.20M	$74.16M	$62.28M	$36.46M
Current Liabilities	$17.82M	$19.80M	$22.25M	$23.08M	$20.10M
Total Debt	$25.12M	$24.73M	$24.34M	$24.01M	$5.75M
Total Liabilities	$39.30M	$40.94M	$43.04M	$43.53M	$24.71M
Retained Earnings	-$674.64M	-$684.02M	-$691.77M	-$704.76M	-$712.32M
Shareholders' Equity	$46.71M	$38.26M	$31.12M	$18.75M	$11.75M
Working Capital	$48.84M	$40.51M	$33.48M	$24.68M	$14.64M

PASG Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$13.85M	-$6.33M	-$4.85M	-$6.48M	-$12.99M
Free Cash Flow	-$13.85M	-$6.33M	-$4.85M	-$6.48M	-$12.99M
Depreciation & Amortisation	$201.00K	$169.00K	$181.00K	$177.00K	$129.00K
Stock-Based Compensation	$858.00K	$923.00K	$611.00K	$609.00K	$556.00K
Investing Cash Flow	$39.63M	$585.00K	$0.00	$0.00	$20.00K
Financing Cash Flow	$0.00	$14.00K	$0.00	$9.00K	$0.00
Net Change in Cash	$25.78M	-$5.73M	-$4.85M	-$6.47M	-$12.97M

Market Snapshot

About

Passage Bio is a clinical-stage genetic medicines company focused on developing AAV-delivered gene therapies for central nervous system disorders. The company leverages its platform to target rare neurological diseases with potentially transformative one-time treatments, aiming to address significant unmet medical needs in CNS conditions.